Theriva Biologics Files Routine 8-K, No New Material Events

Ticker: TOVX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 894158

Theriva Biologics, Inc. 8-K Filing Summary
FieldDetail
CompanyTheriva Biologics, Inc. (TOVX)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulatory-filing, compliance

TL;DR

**Theriva Biologics filed a routine 8-K, no major news to move the stock.**

AI Summary

Theriva Biologics, Inc. filed an 8-K on January 8, 2024, primarily to disclose general information and confirm its current registration details with the SEC. This filing, under Regulation FD, does not announce any new material events like acquisitions, earnings, or significant financial changes. For investors, this means there's no immediate new information to impact their investment decision, and the company is simply maintaining its regulatory compliance, which is a neutral signal.

Why It Matters

This filing is a standard regulatory update, indicating Theriva Biologics is maintaining compliance but not revealing any new information that would directly affect its stock price or business operations.

Risk Assessment

Risk Level: low — This 8-K is a routine administrative filing with no new material information, posing no immediate risk or opportunity.

Analyst Insight

A smart investor would note this as a routine compliance filing and not expect any immediate stock price movement based solely on this 8-K. Further research into the company's actual business operations and upcoming catalysts would be necessary.

Key Numbers

  • 2024-01-08 — Date of Report (The date the earliest event reported in this 8-K occurred.)
  • 001-12584 — Commission File No. (The SEC file number for Theriva Biologics, Inc.)
  • 13-3808303 — IRS Employer Identification No. (The IRS EIN for Theriva Biologics, Inc.)

Key Players & Entities

  • Theriva Biologics, Inc. (company) — the registrant filing the 8-K
  • Nevada (company) — state of incorporation for Theriva Biologics, Inc.
  • 001-12584 (dollar_amount) — Commission File Number for Theriva Biologics, Inc.
  • 13-3808303 (dollar_amount) — IRS Employer Identification Number for Theriva Biologics, Inc.
  • 9605 Medical Center Drive, Suite 270 Rockville, Maryland 20850 (company) — address of principal executive offices for Theriva Biologics, Inc.
  • (301) 417-4364 (dollar_amount) — registrant's telephone number

Forward-Looking Statements

  • Theriva Biologics will continue to file routine regulatory documents without significant new disclosures in the near term. (Theriva Biologics, Inc.) — high confidence, target: 2024-03-31

FAQ

What is the primary purpose of this 8-K filing by Theriva Biologics, Inc.?

The primary purpose of this 8-K filing by Theriva Biologics, Inc. on January 8, 2024, is to provide a 'Current Report' under Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'. It appears to be a routine update without announcing a specific new material event.

What is the date of the earliest event reported in this filing?

The date of the earliest event reported in this filing is January 8, 2024, as stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.

Where are Theriva Biologics, Inc.'s principal executive offices located?

Theriva Biologics, Inc.'s principal executive offices are located at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850.

What is Theriva Biologics, Inc.'s state of incorporation?

Theriva Biologics, Inc.'s state of incorporation is Nevada.

Does this 8-K filing indicate any significant corporate actions like an acquisition or a major financial transaction?

No, this 8-K filing does not indicate any significant corporate actions like an acquisition, a major financial transaction, or an earnings announcement. The 'ITEM INFORMATION' sections only list 'Regulation FD Disclosure' and 'Financial Statements and Exhibits', which are general categories and do not specify a new material event.

Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-08 08:10:38

Key Financial Figures

  • $0.001 — h registered Common stock, par value $0.001 per share TOVX NYSE American Indica

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Theriva Biologics, Inc. (the "Company") will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the Company presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the Company presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company's Company presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Presentation of Theriva Biologics, Inc., dated January 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.